By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Mayne Pharma Limited 

1538 Main North Road

Salisbury South  South Australia  5106   Australia
Phone: 61-8-8209-2666 Fax: 61-8-8281-6998


SEARCH JOBS

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 125 clients worldwide.

YEAR FOUNDED:

1845

LEADERSHIP:

Founder: Francis Hardey Faulding

CEO: Scott Richards

CMO (Medical):

CFO: Eric Evans (US) and Mark Cansdale (Global)

CSO (Scientific): Ilana Stancovski (Global)

JOBS:

Please click here for Mayne job opportunities.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Mayne Pharma
Employees:
Symbol: 
 









Company News
Mayne Pharma Appoints Executive Vice President at Metrics Contract Services 7/19/2017 10:15:37 AM
Mayne Pharma, Metrics Contract Services , Designate Stability Storage Facility "Center Of Excellence" 7/12/2017 11:35:02 AM
Mayne Pharma Announces FDA Approval And Immediate Launch Of Doxycycline Hyclate IR Tablets, First Generic To Acticlate 6/16/2017 9:19:35 AM
Mithra Pharmaceuticals Agrees Exclusive Long-Term License And Supply Agreement With Mayne Pharma To Commercialize Myring In The U.S. 2/28/2017 9:06:01 AM
H2-Phama Aquires Rights to 15 Mayne Pharma Products 12/6/2016 10:41:17 AM
Mayne Pharma Pays $50 Million to GlaxoSmithKline (GSK) for Portfolio Of Dermatology Foam Products and Assets 8/18/2016 5:52:43 AM
Mayne Pharma Commits $80 Million to North Carolina Expansion After Acquiring 42 Products from Allergan (AGN), Teva (TEVA) 8/4/2016 6:48:20 AM
Corbett Leaves Woolworths For Mayne Pharma 6/28/2016 11:52:48 AM
Mayne Pharma Expands into U.S. Through the $652 Million Acquisition of 42 Generic Drugs From Allergan (AGN) and Teva (TEVA) 6/28/2016 5:56:47 AM
Mayne Pharma Receives FDA Approval For Dofetilide Capsules, A Generic Alternative To TIKOSYN, And Is Awarded 180 Days Market Exclusivity 6/7/2016 1:52:11 PM
123
//-->